PERSPECTIVES

RIPK3 Takes Another Deadly Turn
CELL BIOLOGY
Blocking an enzyme involved in necroptosis may prove toxic by promoting another form of cell death. P rogrammed necrosis, or necroptosis, is a form of cell death with important roles in many inflammatory conditions, such as innate antiviral responses and atherosclerosis. It is a messy process, characterized by cell swelling and eventual rupture that releases contents into the surroundings, triggering inflammation. Initially considered an unregulated response to nonspecifi c stress, necroptosis is now understood to be controlled by signaling pathways that intersect with the regulation of apoptosis, a wellcharacterized programmed cell death mechanism. By contrast, apoptosis is relatively neat and does not trigger an infl ammatory response. Determining how a cell succumbs to one form of cell death and not the other may guide the development of therapeutic strategies for acute and chronic infl ammatory diseases. On page 1357 of this issue, Newton et al. ( 1) elucidate how the two cell death mechanisms intersect, and discover that disrupting one process leads to a surprising consequence-death by the other.
During apoptosis, the cell dismantles itself through internal proteases (caspases) that are activated in response to "death receptors," members of the tumor necrosis factor (TNF) receptor family. Necroptosis relies on receptor interacting protein kinase 1 (RIPK1) and RIPK3. These enzymes also respond to the TNF receptor, but as well to toll-like receptor 3 (TLR3), TLR4, and the T cell antigen receptor. Cells are sensitized to necroptosis when certain proteins of the apoptosis mechanism-caspase 8 or its activator, Fas-associated protein with death domain (Fadd)-are inhibited. In the absence of active caspase 8, RIPK1 phosphorylates and activates RIPK3, which in turn phosphorylates the protein mixed lineage kinase domain-like (MLKL), leading to plasma membrane rupture and necrosis ( 2) .
Studies in mice showed that genetic inactivation of RIPK3 corrected many inflammatory conditions caused by tissue-specifi c defi ciency of Fadd or caspase 8 ( 2) . Similarly, acute injury-induced inflammation, such as that triggered by drugs or ischemiareperfusion, was ameliorated in mice lacking RIPK3. These fi ndings pointed to inhibition of the kinase function of RIPK3 as a promising therapeutic strategy for acute and chronic infl ammatory diseases.
To test the feasibility of this therapeutic approach, Newton et al. generated mice genetically engineered to express an enzymatically inactive version of RIPK3 in which aspartic acid at position 161 is replaced with asparagine (RIPK3-D161N). Surprisingly, whereas mice lacking RIPK3 were viable, animals expressing RIPK3-D161N died at mid-gestation from abnormal vascular devel- (Bottom) RIPK3 prevents cell death by apoptosis, possibly by phosphorylating (P) a substrate (yet unknown protein "X") that blocks the assembly of a proapoptotic complex (Fadd, caspase 8, RIPK1, and RIPK3). However, an inactive form of RIPK3 (D161N) stimulates apoptosis. This may occur through a conformational change that allows the inactive form to promote assembly of the proapoptotic complex.
Jianke
CREDIT: H. MCDONALD/SCIENCE could offer the opportunity to reconstruct pathophysiological phenotypes characterized by specifi c protein expression patterns and not necessarily hard-coded at the DNA level.
Ongoing developments in the analysis of ancient biomolecules and integration of highthroughput methods to sequence multiple categories of ancient biomolecules have the potential to provide insights into biological processes in the distant past. Ancient DNA analysis remains at the forefront of ancient biomolecular studies ( 12, 13) . Ancient proteomics has the potential to complement this exciting work-for example, to shed light on disease processes that cannot be captured by DNA studies.
PERSPECTIVES
Epstein-Barr Virus Turns 50
VIROLOGY
Paul M. Lieberman
Fifty years after the discovery of Epstein-Barr virus and its association with cancer, a vaccine or therapy for the virus remains elusive.
T his month marks the 50th anniversary of the discovery of Epstein-Barr virus (EBV) as the fi rst human tumor virus. In March 1964, a team led by Anthony Epstein identifi ed herpesvirus-like particles in cultured tumor cells derived from African Burkitt's lymphoma tissue ( 1) . At that time, the idea that a virus caused human cancer was met with some skepticism because the theory that cancer was infectious had been dismissed in the previous century. Stalwart investigators continued to track EBV until the viral culprit was declared a class I carcinogen by the International Agency for Research on Cancer and the World Health Organization in the late 1990s. Despite the consensus that EBV is a bona fi de tumor virus, the mechanisms of cancer causation by EBV remain an area of active investigation and controversy 50 years since its initial discovery.
One of the most confounding findings relating to the association of EBV with rare cancers is that EBV prevalence in the normal population is extraordinarily high, reaching over 90% of the adult population worldwide. Because EBV is a member of the herpesvirus family, it is very adept at establishing a long-term latent infection. Exposure to EBV can be detected by serology, and latent forms of EBV can be readily detected by molecular methods in a small percentage of B lymphocytes from healthy individuals. Furthermore, EBV was identified as a major causative agent of infectious mononucleosis, which seemed incongruent with its role in cancer causality. How could a relatively common virus be the cause of an endemic childhood cancer in Africa?
Viral causes of animal cancers had been known since 1911, when Peyton Rous discovered that retroviruses cause cancers in chickens. But it was not until the discovery in 1968 that viruses related to EBV were responsible for T cell lymphomas in nonhuman primates that the case for EBV-dependent tumorigenesis became more compelling. EBV was soon found to be highly effi cient at transforming quiescent human B lymphocytes into contin-
The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104-4265, USA. E-mail: lieberman@wistar.org opment of the yolk sac. This phenotype was reminiscent of mice that lack Fadd or caspase 8. While mice lacking Fadd or caspase 8 succumbed to extensive necrosis during embryogenesis, the lethality in RIPK3-D161N mice was caused by extensive caspase-dependent apoptosis. Mice expressing RIPK3-D161N and also lacking caspase 8 were normal, but developed a lymphoproliferative disease akin to that caused by inactivating mutations in Fas, a member of the TNF receptor family that stimulates apoptosis. Newton et al. show that induced expression of RIPK3-D161N in adult mice triggered the formation of a complex containing Fadd, caspase 8, RIPK1, and RIPK3 that caused massive apoptosis in multiple tissues and lethality. Although RIPK1 is present in this death-inducing complex, blocking its kinase activity did not prevent apoptosis. Moreover, embryonic lethality of RIPK3-D161N mice was rescued by RIPK1 defi ciency. Thus, although there is an overlapping set of proteins (Fadd, caspase 8, RIPK1, and RIPK3) that are involved in necroptosis and RIPK3-D161N-induced apoptosis, the molecular mechanisms that drive these two cell death responses are distinct.
How can we reconcile the lethal phenotype of RIPK3-D161N mice when animals lacking RIPK3 were born alive with no overt abnormalities? One explanation is that RIPK3 phosphorylates and inactivates a substrate that prevents assembly of the Fadd-caspase 8-RIPK1-RIPK3 death-inducing complex (see the fi gure). In this regard, it is noteworthy that the activities of Fadd, RIPK1, and RIPK3 are controlled by phosphorylation ( 3, 4) . Perhaps RIPK3 directly phosphorylates one or more of these proteins to control the assembly of this RIPK3-associated apoptosis-inducing complex.
Although inhibition of RIPK3 kinase activity is a plausible cause of apoptosis in RIPK3-D161N cells and mice, other mechanisms are also possible. For example, mice that express a single allele of D161N were viable. Because gene dosage is important, the phenotypes cannot be entirely attributed to lack of kinase activity. Previous studies show that a form of RIPK3 in which the kinase domain has been deleted causes spontaneous formation of RIP homotypic interaction motif ( 5) (RHIM)-dependent amyloid fi brils ( 6) . This indicates that the kinase domain may functionally "mask" the RHIM to prevent inadvertent activation. In this scenario, the D161N mutation could alter the conformation of RIPK3 such that the RHIM is exposed for binding to RIPK1. This model predicts that the kinase and RHIM domains collaborate to control scaffolding of the necroptotic and apoptotic machineries. This type of scaffolding function for kinase domains has been observed with oncogenic kinases such as B-Raf ( 7). Interestingly, a much lower amount of RIPK3-D161N was expressed compared to wild-type RIPK3, which may be attributed to a conformational change that leads to protein instability. The therapeutic effi cacy of RIPK3 kinase inhibitors ( 8) will depend on whether they similarly promote assembly of this apoptosis scaffold. In contrast to RIPK3 ( 9) , mice expressing kinase inactive RIPK1 were viable ( 1) . As such, pharmacologic inhibition of RIPK1 may prove to be a more viable option in the clinic.
Although compelling evidence indicates that RIPK3 does not participate in death receptor-induced apoptosis, RIPK3 was originally identifi ed as an inducer of apoptosis (10) (11) (12) . Newton et al. show that regardless of the mechanism, RIPK3 can indeed function as an apoptosis regulator. In that sense, RIPK3 biology has come full circle. The challenge is to determine how RIPK3-dependent apoptosis is induced and whether it has any unique functions in physiology.
